Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thela...
All content for The Lancet in conversation with is the property of The Lancet Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thela...
Dr Oriol Mitjà and Dr Hypolite Muhindo Mavoko on mpox
The Lancet in conversation with
26 minutes
1 year ago
Dr Oriol Mitjà and Dr Hypolite Muhindo Mavoko on mpox
On August 14th, the World Health Organisation declared a public health emergency of international concern in relation to mpox. This was motivated, in part, by the emergence of a concerning new strain of mpox, clade 1b, which has spread rapidly across Central Africa. Joining me this week to discuss important clinical aspects of the current mpox outbreak are Dr Oriol Mitja, Associate Professor at the Germans Trias Research Institute in Barcelona, and Dr Hypolite Muhindo Mavoko from the Departme...
The Lancet in conversation with
Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thela...
